Related references
Note: Only part of the references are listed.The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner
Lisa C. Huesemann et al.
CELL CYCLE (2020)
Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations
Daniel Y. Zhang et al.
CLINICAL CANCER RESEARCH (2020)
ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
Priya Kumthekar et al.
CLINICAL CANCER RESEARCH (2020)
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas
Ricardo Gargini et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer
Jim Kallarackal et al.
PLOS ONE (2020)
Visualizing and interpreting cancer genomics data via the Xena platform
Mary J. Goldman et al.
NATURE BIOTECHNOLOGY (2020)
A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
Yixin Liu et al.
FRONTIERS IN ONCOLOGY (2019)
Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer
Shunyu Hou et al.
PLOS ONE (2018)
The unfolded protein response and endoplasmic reticulum protein targeting machineries converge on the stress sensor IRE1
Diego Acosta-Alvear et al.
ELIFE (2018)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung et al.
NATURE PROTOCOLS (2017)
Transcriptome Analysis of Wnt3a-Treated Triple-Negative Breast Cancer Cells
Sylvie Maubant et al.
PLOS ONE (2015)
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
Mitsuya Itoh et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Radiosensitization of malignant gliomas following intracranial delivery of paclitaxel biodegradable polymer microspheres Laboratory investigation
Patrik Gabikian et al.
JOURNAL OF NEUROSURGERY (2014)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Polo-like Kinase 1: A Potential Therapeutic Option in Combination with Conventional Chemotherapy for the Management of Patients with Triple-Negative Breast Cancer
Virginie Maire et al.
CANCER RESEARCH (2013)
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Jan Drappatz et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang et al.
NUCLEIC ACIDS RESEARCH (2013)
TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer
Virginie Maire et al.
PLOS ONE (2013)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest
P. Russell et al.
ONCOGENE (2012)
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel
Uchenna O. Njiaju et al.
PHARMACOGENETICS AND GENOMICS (2012)
Translocon-Associated Protein Subunit Trap-γ/Ssr3 Is Required for Vascular Network Formation in the Mouse Placenta
Yasuka L. Yamaguchi et al.
DEVELOPMENTAL DYNAMICS (2011)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Ingrid E. Wertz et al.
NATURE (2011)
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
Joshua A. Bauer et al.
CLINICAL CANCER RESEARCH (2010)
Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials
Nicolai Juul et al.
LANCET ONCOLOGY (2010)
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Lajos Pusztai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules
A. Mielgo et al.
ONCOGENE (2009)
Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability
Takao Iwawaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment
Katja Janssen et al.
BLOOD (2007)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
Charles Swanton et al.
CANCER CELL (2007)
Simultaneous induction of the four subunits of the TRAP complex by ER stress accelerates ER degradation
Koji Nagasawa et al.
EMBO REPORTS (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study
Z Lidar et al.
JOURNAL OF NEUROSURGERY (2004)
Paclitaxel nanoparticles for the potential treatment of brain tumors
JM Koziara et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis
K Shimada et al.
CARCINOGENESIS (2004)
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Substrate-specific function of the translocon-associated protein complex during translocation across the ER membrane
RD Fons et al.
JOURNAL OF CELL BIOLOGY (2003)
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R Rosell et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
